These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 36750890)
1. Discovery of Highly Potent CRBN Ligands and Insight into Their Binding Mode through Molecular Docking and Molecular Dynamics Simulations. Yan J; Zheng Z ChemMedChem; 2023 Mar; 18(5):e202200573. PubMed ID: 36750890 [TBL] [Abstract][Full Text] [Related]
2. Computational investigations of indanedione and indanone derivatives in drug discovery: Indanone derivatives inhibits cereblon, an E3 ubiquitin ligase component. Nayek U; Basheer Ahamed SI; Mansoor Hussain UH; Unnikrishnan MK; Abdul Salam AA Comput Biol Chem; 2022 Dec; 101():107776. PubMed ID: 36252444 [TBL] [Abstract][Full Text] [Related]
3. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678 [TBL] [Abstract][Full Text] [Related]
4. Discovery of potential novel CRBN modulators by virtual screening and bioassay. Xiong F; Kong L; Chen L; Xue M; Cao F; Zhang S; Li H; Yan H; Li Y; Zuo Z Eur J Med Chem; 2022 Jun; 236():114355. PubMed ID: 35413617 [TBL] [Abstract][Full Text] [Related]
5. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function. Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201 [TBL] [Abstract][Full Text] [Related]
6. Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon. Akuffo AA; Alontaga AY; Metcalf R; Beatty MS; Becker A; McDaniel JM; Hesterberg RS; Goodheart WE; Gunawan S; Ayaz M; Yang Y; Karim MR; Orobello ME; Daniel K; Guida W; Yoder JA; Rajadhyaksha AM; Schönbrunn E; Lawrence HR; Lawrence NJ; Epling-Burnette PK J Biol Chem; 2018 Apr; 293(16):6187-6200. PubMed ID: 29449372 [TBL] [Abstract][Full Text] [Related]
7. Synthesis of novel glutarimide ligands for the E3 ligase substrate receptor Cereblon (CRBN): Investigation of their binding mode and antiproliferative effects against myeloma cell lines. Krasavin M; Adamchik M; Bubyrev A; Heim C; Maiwald S; Zhukovsky D; Zhmurov P; Bunev A; Hartmann MD Eur J Med Chem; 2023 Jan; 246():114990. PubMed ID: 36476642 [TBL] [Abstract][Full Text] [Related]
8. Development of Substituted Phenyl Dihydrouracil as the Novel Achiral Cereblon Ligands for Targeted Protein Degradation. Xie H; Li C; Tang H; Tandon I; Liao J; Roberts BL; Zhao Y; Tang W J Med Chem; 2023 Feb; 66(4):2904-2917. PubMed ID: 36749666 [TBL] [Abstract][Full Text] [Related]
9. Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs. Chamberlain PP; Lopez-Girona A; Miller K; Carmel G; Pagarigan B; Chie-Leon B; Rychak E; Corral LG; Ren YJ; Wang M; Riley M; Delker SL; Ito T; Ando H; Mori T; Hirano Y; Handa H; Hakoshima T; Daniel TO; Cathers BE Nat Struct Mol Biol; 2014 Sep; 21(9):803-9. PubMed ID: 25108355 [TBL] [Abstract][Full Text] [Related]
10. [Development of novel cereblon modulators and their target molecules]. Ito T Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190 [TBL] [Abstract][Full Text] [Related]
11. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide. Fischer ES; Böhm K; Lydeard JR; Yang H; Stadler MB; Cavadini S; Nagel J; Serluca F; Acker V; Lingaraju GM; Tichkule RB; Schebesta M; Forrester WC; Schirle M; Hassiepen U; Ottl J; Hild M; Beckwith RE; Harper JW; Jenkins JL; Thomä NH Nature; 2014 Aug; 512(7512):49-53. PubMed ID: 25043012 [TBL] [Abstract][Full Text] [Related]
12. Exploiting ubiquitin ligase cereblon as a target for small-molecule compounds in medicine and chemical biology. Ito T; Yamaguchi Y; Handa H Cell Chem Biol; 2021 Jul; 28(7):987-999. PubMed ID: 34033753 [TBL] [Abstract][Full Text] [Related]
13. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Lopez-Girona A; Mendy D; Ito T; Miller K; Gandhi AK; Kang J; Karasawa S; Carmel G; Jackson P; Abbasian M; Mahmoudi A; Cathers B; Rychak E; Gaidarova S; Chen R; Schafer PH; Handa H; Daniel TO; Evans JF; Chopra R Leukemia; 2012 Nov; 26(11):2326-35. PubMed ID: 22552008 [TBL] [Abstract][Full Text] [Related]
14. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Sievers QL; Petzold G; Bunker RD; Renneville A; Słabicki M; Liddicoat BJ; Abdulrahman W; Mikkelsen T; Ebert BL; Thomä NH Science; 2018 Nov; 362(6414):. PubMed ID: 30385546 [TBL] [Abstract][Full Text] [Related]
15. Combined scaffold hopping, molecular screening with dynamic simulation to screen potent CRBN ligands. Yan J; Sun S; Zhang W; Li P; Zheng Z J Cell Biochem; 2021 May; ():. PubMed ID: 33938033 [TBL] [Abstract][Full Text] [Related]
16. Molecular mechanisms of cereblon-based drugs. Asatsuma-Okumura T; Ito T; Handa H Pharmacol Ther; 2019 Oct; 202():132-139. PubMed ID: 31202702 [TBL] [Abstract][Full Text] [Related]
17. Discovery of CRBN as a target of thalidomide: a breakthrough for progress in the development of protein degraders. Yamamoto J; Ito T; Yamaguchi Y; Handa H Chem Soc Rev; 2022 Aug; 51(15):6234-6250. PubMed ID: 35796627 [TBL] [Abstract][Full Text] [Related]
18. The E3 ubiquitin ligase component, Cereblon, is an evolutionarily conserved regulator of Wnt signaling. Shen C; Nayak A; Neitzel LR; Adams AA; Silver-Isenstadt M; Sawyer LM; Benchabane H; Wang H; Bunnag N; Li B; Wynn DT; Yang F; Garcia-Contreras M; Williams CH; Dakshanamurthy S; Hong CC; Ayad NG; Capobianco AJ; Ahmed Y; Lee E; Robbins DJ Nat Commun; 2021 Sep; 12(1):5263. PubMed ID: 34489457 [TBL] [Abstract][Full Text] [Related]
19. Molecular and Structural Characterization of Lenalidomide-Mediated Sequestration of eIF3i. Lin Z; Shen D; Yang B; Woo CM ACS Chem Biol; 2022 Nov; 17(11):3229-3237. PubMed ID: 36325969 [TBL] [Abstract][Full Text] [Related]
20. Discovery of novel potential CRBN modulators through structure-based virtual screening and bioassay. Xiong F; Zhou LY; Chen L; Cao F; Zhang S; Zuo Z J Mol Graph Model; 2022 Dec; 117():108325. PubMed ID: 36088765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]